The State of European Biotech Seed Funding in 2025

European biotech is attracting more seed capital than ever before, but the quality of early-stage investors varies enormously — and for a biotech founder raising their first institutional round, the choice of investor is among the most consequential decisions you will make. The right seed investor can accelerate your regulatory pathway, connect you to pharmaceutical partnership conversations that would take years to initiate independently, and help you build a board that positions you well for the capital-intensive development stages ahead. The wrong one can create governance complications, introduce misaligned incentive structures, and leave you without the support you need when you face the inevitable setbacks that characterise biotech development. Here is what to look for.

The European Biotech Seed Landscape in 2025

The European biotech seed market has undergone a significant transformation over the past decade. The traditional model — in which academic spinouts bootstrapped on university grants until they could attract a Series A from a specialist life sciences fund — has given way to a more dynamic ecosystem with multiple financing options at the earliest stages. Angel networks specialising in life sciences have grown substantially, university seed funds have expanded, and a growing number of generalist deep tech VCs have developed sufficient life sciences expertise to make meaningful early-stage investments.

The data reflects this evolution. European biotech seed rounds in 2024 averaged approximately €3.2 million, up from €1.8 million in 2019. The number of European biotech companies that raised institutional seed rounds in 2024 exceeded 200 for the first time. And crucially, the geographic diversity of European biotech seed investment has expanded significantly — while the UK continues to lead in absolute numbers, strong biotech seed ecosystems have emerged in Germany, the Netherlands, France, Denmark, and Switzerland, each with their own investor communities, regulatory expertise, and proximity to potential pharmaceutical partners.

The increase in available capital has been accompanied by an increase in investor sophistication. The best European biotech seed investors today have genuine scientific and clinical expertise, not just financial capability. They understand the difference between preclinical and clinical evidence, they can evaluate a patent landscape without relying entirely on the founding team's assessment, and they have relationships with regulatory agencies, contract research organisations, and pharmaceutical business development teams that they can deploy on behalf of portfolio companies.

How Machine Learning Is Reshaping Biotech Timelines

The convergence of machine learning and biology is one of the most significant scientific developments of the current decade, and it is reshaping the biotech investment landscape in fundamental ways. The traditional biotech development timeline — from target identification to clinical proof of concept — typically took seven to ten years and cost hundreds of millions of dollars. Machine learning is compressing several of the most time-consuming phases of this timeline.

In drug discovery, machine learning models trained on protein structure data, molecular interaction databases, and clinical trial outcomes are dramatically accelerating the identification of drug candidates. AlphaFold's protein structure prediction capability, now available to researchers worldwide, has effectively removed one of the core bottlenecks in structure-based drug design. European companies including LabGenius, EvolutionaryScale's European collaborators, and several university spinouts are building proprietary machine learning approaches for antibody engineering, small molecule design, and target identification that are demonstrating substantially faster timelines than conventional methods.

In clinical trial design, machine learning is enabling more efficient patient stratification, endpoint selection, and trial design — reducing both the time and the cost required to generate statistically meaningful evidence. Adaptive trial designs powered by Bayesian statistical methods allow trial parameters to evolve as evidence accumulates, reducing the number of patients required for successful trials and accelerating the time from Phase 1 safety trials to Phase 2 efficacy data. For investors, this compression of development timelines means that seed-stage investments in companies with strong machine learning capabilities may reach clinical milestones faster than conventional biotech would suggest.

The Synthetic Biology Opportunity

Beyond drug discovery, synthetic biology is emerging as one of the most compelling investment themes in European biotech. Synthetic biology — the engineering of biological systems to produce desired molecules, materials, or functional outcomes — is moving from a research curiosity to a platform technology with applications in pharmaceuticals, agriculture, industrial chemicals, and consumer products. European companies are competitive across multiple synthetic biology domains.

The tools powering synthetic biology — DNA synthesis, gene editing, metabolic engineering, high-throughput screening — have all become dramatically cheaper and more reliable over the past decade. The cost of sequencing a human genome, which stood at $100 million in 2001, has now fallen below $200. Gene synthesis costs have fallen at a similar rate. These cost reductions are enabling experiments that were previously impossible and companies that would previously have required ten times the capital to reach commercially meaningful demonstrations.

European regulatory frameworks for synthetic biology products — particularly in agriculture and food applications — are evolving, with the EU's updated New Genomic Techniques regulation creating clearer pathways for products created through precision gene editing. For investors, this regulatory evolution is significant: it means that some synthetic biology applications that were previously blocked from European markets by ambiguous or overly restrictive regulation are now addressable, expanding the commercial opportunity for European synthetic biology companies.

What Biotech Founders Should Look for in a Seed Investor

Given the complexity of biotech development and the specific challenges European biotech founders face, we have developed a framework for what founders should prioritise when selecting their seed investor — beyond the obvious dimensions of valuation and check size.

The first priority is scientific credibility. Your seed investor will serve as a signal to subsequent investors, pharmaceutical partners, and regulatory contacts about the quality and credibility of your scientific programme. An investor who is known in the life sciences community for intellectual rigour, scientific honesty, and high-quality portfolio selection provides a credibility signal that accelerates every subsequent relationship the company needs to build. An investor who is primarily a generalist without genuine life sciences expertise provides a much weaker signal.

The second priority is regulatory and clinical expertise. Biotech development is regulated, and navigating the regulatory pathway from preclinical work to clinical trials is a specialised skill that most early-stage companies lack. An investor who has been through multiple regulatory processes — who knows how to structure an IND application, who understands the EMA's scientific advice process, who has relationships with key opinion leaders in your therapeutic area — can save years and tens of millions of euros in navigating the regulatory pathway more efficiently. This expertise is more valuable than it appears at the seed stage, because the choices made in early development — about the clinical endpoint to target, the patient population to enrol, the biomarker strategy to pursue — have compounding effects on the difficulty and cost of subsequent development stages.

The third priority is pharmaceutical network access. The eventual monetisation of most biotech programmes involves some form of pharmaceutical partnership — licensing, co-development, or acquisition. The seed investor who can introduce you to business development teams at relevant pharmaceutical companies, facilitate scientific discussions with therapeutic area heads, and help you understand what pharmaceutical acquirers look for in due diligence is providing a form of value that is genuinely rare and genuinely important. In our experience, warm introductions from trusted investors to pharma business development teams result in partnership discussions that would otherwise take two to three years to initiate through cold outreach.

The Capital Efficiency Imperative in European Biotech

One structural reality of European biotech that differs from the US context is capital efficiency. European biotech companies are typically required to achieve more with less — to reach clinical proof-of-concept milestones on seed and pre-seed funding that their US counterparts might achieve with two or three times the capital. This is partly a function of the smaller average size of European seed rounds, partly a function of the higher cost of US clinical trials relative to European ones, and partly a function of the broader European venture ecosystem's preference for capital-efficient business models.

For founders, this capital efficiency imperative is a constraint that drives strategic choices. European biotech companies tend to be more disciplined about selecting the highest-probability clinical indication for their first programme, rather than spreading resources across multiple therapeutic areas simultaneously. They tend to pursue collaborative research agreements and academic partnerships to extend their scientific capabilities without the cost of full laboratory buildout. And they tend to think carefully about European versus global regulatory strategy from the outset, recognising that European clinical data has real value for US regulatory submissions.

For investors, the capital efficiency of European biotech is an advantage. Companies that are disciplined about capital allocation, that have made hard choices about scientific focus, and that have found creative ways to extend their runway without dilution are often better managed — and more resilient through the inevitable setbacks of biotech development — than companies that have raised more capital but have used it less efficiently.

Hilberts AI Capital is actively building our biotech portfolio, focusing particularly on companies at the intersection of machine learning and biology, synthetic biology for industrial applications, and novel modality therapeutics with strong European regulatory pathways. If you are building a biotech company at the seed stage, get in touch — we would be glad to learn about your science and your programme.